Insights

The New Gold Standard of Drug Commercialization

Manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach…

Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard

The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…

A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

Today we have access to more data, from more sources than we could ever dream possible. Living in a digital world, we increasingly need the ability to efficiently and effectively process this data for insights and…

Why are We Settling for Mediocre Patient Services Programs?

Patient Services Programs Are Falling Short To give credit where credit is due, pharmaceutical manufacturers make a tremendous – and well-intended – effort to alleviate the product access obstacles and burdens patients and providers often endure…

Articles

MARKET ACCESS AND TREATMENT OUTCOMES: Shifting From the Volume of Data to the Value of Insights

From Volume to Value: “The best prescription is insightful knowledge.” Former Surgeon General of the United States Dr. C. Everett Koop once aphoristically said, “The best prescription is knowledge.” This thought permeates much of what drives…

Population Health Partnerships To Advance Value-Based Care

The business model for health care in the United States is evolving from a volume-driven model to a consumer-centric, value-driven model. As such, there are new competencies required of hospitals and health systems to effectively manage…

Mitigating Risk: When A Curveball Threatens Your Product’s Launch

In this 3-minute video, Mike DeLaroche shares a new commercialization model that mitigates risk and combats curveballs that manufacturers cannot predict when launching products.

Italy Tackles HTA, Pricing and Reimbursement Reforms

In July, new legislation set to overhaul the way pharmaceuticals are priced in Italy was finally implemented, following an announcement that dates all the way back to August 2019. The provision, which was signed by then…

An Illustration: Transforming the Patient Experience

In October 2020, EVERSANA and NORD teamed up with rare disease experts to brainstorm how to transform the patient journey and create more moments that matter. Hosted by EVERSANA CEO Jim Lang and moderated by Faruk…

eBook – 2020 Stories That Shaped Commercialization

While many industries hit the pause button on their operations this year, the pharmaceutical industry never stopped, propelling new innovations to better serve patients, providers and stakeholders. At EVERSANA, we worked closely with manufacturers to tackle…

When A Curveball Threatens Your Product’s Launch

Download the article to learn about proven strategies to help shield your company from unwelcome surprises during launch by reducing your financial exposure and creating a more stable and flexible launch operation.

CBI Hub, SPP and eServices Insights: Leveraging Behavioral Health Technology

The Science of Human Resiliency — Behavioral Health Technology to Improve Patient Outcomes and Adherence Over the past several years, pharmaceutical manufacturers have been in pursuit of improving the patient experience by reducing time-to-treatment, developing a…

PharmaVOICE Commercial Influencers: Greg Skalicky

In a special focus on Commercial Influencers, PharmaVOICE Editor Taren Grom sat down with EVERSANA’s Chief Revenue Officer Greg Skalicky to discuss approaches to commercial strategies and how disruptive companies are changing the market to better reach and engage patients. The conversation covered commercialization trends, how…

Advancing Beyond the Traditional Patient Adherence Model

Showcase Featured In PharmaVOICE – October 2020 Delivering value in the era of empowered patients renders the one-size-fits all patient services program obsolete. Not every treatment journey is consistently linear within a disease state because patients…